Several S1P modulators have been approved for MS treatment: Fingolimod (FTY720) [3, 4], Siponimod (BAF312) [5], Ozanimod (RPC1063) [6, 7], and Ponesimod (ACT-128800) [8]. This evidence concerns the gene MBTPS1 and myeloid sarcoma.